HemaXellerate is under clinical development by Regen BioPharma and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect HemaXellerate’s likelihood of approval (LoA) and phase transition for Aplastic Anemia took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their HemaXellerate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
HemaXellerate cell therapy is under development for the treatment of aplastic anemia, and myelosuppression. HemaXellerate provides the optimum mix of growth factors that stimulate the bone marrow to produce blood cells naturally.
Regen BioPharma overview
Regen BioPharma is an immunology and immunotherapy solutions provider. Its product pipeline includes HemaXellerate, DiffronC and dCellVax small molecule targeting cancer stem cell genes, telomeres, and genomic integrity. Regen BioPharma provides products for aplastic anemia, myelodysplastic syndrome, solid tumors and acute leukemia, breast cancer, hematopoiesis, and liver cancer, among others. It concentrates on the development of immunotherapies and cancer stem cell therapies. The company spans its expertise in the development of therapies including small molecules, stem cell treatments and the body’s own immune system. Regen BioPharma is headquartered in La Mesa, California, the US.
Quick View HemaXellerate LOA Data
|Highest Development Stage|